These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 31368406)

  • 1. The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants.
    Allyn-Feuer A; Ade A; Luzum JA; Higgins GA; Athey BD
    Pharmacogenomics; 2018 Apr; 19(5):413-434. PubMed ID: 29400612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
    Ivashchenko D; Rusin I; Sychev D; Grachev A
    Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of pharmacogenetic testing on the risk of bleedings and excessive hypocoagulation episodes in the use of warfarin: the first meta-analysis of Russian prospective studies].
    Sychev DA; Ivashchenko DV; Rusin IV
    Ter Arkh; 2014; 86(4):64-71. PubMed ID: 24864470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADME pharmacogenetics: future outlook for Russia.
    Mirzaev KB; Fedorinov DS; Ivashchenko DV; Sychev DA
    Pharmacogenomics; 2019 Jul; 20(11):847-865. PubMed ID: 31368406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacogenetics or "farm-ecogenetics"?].
    Gérard N; Elion J; Krishnamoorthy R
    J Soc Biol; 2000; 194(1):9-13. PubMed ID: 11107543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.
    Umamaheswaran G; Kumar DK; Adithan C
    Indian J Med Res; 2014 Jan; 139(1):27-65. PubMed ID: 24604039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the pharmacogenetic approach to warfarin dosing.
    Glurich I; Burmester JK; Caldwell MD
    Heart Fail Rev; 2010 May; 15(3):239-48. PubMed ID: 18998206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-guided warfarin therapy: current status.
    Tavares LC; Marcatto LR; Santos PCJL
    Pharmacogenomics; 2018 May; 19(7):667-685. PubMed ID: 29701078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.